Because NF-κB activation has been involved in many types of cancer metastasis that are likely induced by its downstream pro-inflammatory cytokines such as IL6 and GM-CSF [60]–[62], targeting NF-κB and its associated pathways may open a possibility for therapeutic intervention of metastatic cancer. This evidence concerns the gene CSF2 and cancer.